WUHAN, Nov. 18 (Xinhua) -- A cardiac surgical system developed by a Chinese research team has made minimally invasive treatment possible for hypertrophic cardiomyopathy, eliminating the need for open-chest surgery and cardiac arrest.
Two papers detailing the underlying research were published in Circulation, an international journal in the field of cardiovascular medicine, on Tuesday, according to Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology in Wuhan, central China's Hubei Province.
The research was led by Professor Wei Xiang, director of the hospital's cardiac surgery department. Inspiration for the device came from him watching a street vendor carving a pineapple.
Hypertrophic cardiomyopathy is a congenital heart condition in which the heart muscle becomes more than twice as thick as normal, posing a major challenge to clinicians worldwide. Patients suffer from chronic chest pain, tightness and shortness of breath, and face risks of arrhythmia and sudden death.
Conventional surgery for obstructive hypertrophic cardiomyopathy requires a 20-centimeter incision through the sternum and is performed on a stopped heart with cardiopulmonary bypass. The surgery is highly invasive, technically demanding and offers limited visibility, resulting in most patients opting for medication, which can only ease symptoms temporarily and does not resolve the underlying obstruction.
In March 2018, Wei noticed how a fruit vendor drove a blade into a pineapple and rotated it to extract the unwanted core in one piece. He wondered whether a similar rotating cutting tool could be inserted through the apex of a beating heart to remove thickened muscle and extract it from the body.
Wei sketched a prototype and tested it on pig hearts. After seven rounds of design iteration, the team finalized the device.
The first patient, who was treated in 2022, was awake and spoke with family members an hour after surgery. The technology has since been used on nearly 1,600 patients with obstructive hypertrophic cardiomyopathy at Tongji Hospital. The researchers say the approach offers particular advantages for surgery on children and teenagers, where smaller cardiac structures demand greater precision.
The papers provide a comprehensive account of the technique's development, clinical evidence, surgical indications, complication management and potential for wider adoption.
In recent years, Wei has been invited to lecture on the technique at leading cardiovascular centers worldwide, and cardiac surgeons from multiple countries have traveled to Wuhan for learning. The team is applying for patents in the European Union, Japan and the Republic of Korea.
"We hope to extend the technique to more regions and hospitals, so that it can surpass conventional open-chest myectomy in the number of operations and benefit more patients," Wei said. ■



